Abstract: Provided herein are compositions of lipid-based nanoparticles, such as exosomes, that comprise a therapeutic agent that activates a tumor suppressor. Also provided are methods of using such compositions to treat a patient having a cancer caused, at least in part, by the loss of the tumor suppressive activity. In particular, exosomes comprising an siRNA that targets mutant p53 are provided along with methods of their use in treating cancer.

Abstract: The present invention provides lipid-based nanoparticles (e.g., liposomes or exosomes) having CD47 on their surface and comprising a therapeutic agent (e.g., a therapeutic protein, an antibody, an inhibitory RNA, and/or a small molecule drug). Furthermore, the present invention provides for use of such lipid-based nanoparticles in therapy.

Abstract: Provided herein are compositions of lipid-based nanoparticles, such as exosomes, that comprise a therapeutic agent that inhibits the activity of an oncogene. Also provided are methods of using such compositions to treat a patient having a cancer caused by the activation of the oncogene. In particular, exosomes comprising an siRNA that targets oncogenic Myc are provided along with methods of their use in treating cancer.

Abstract: Provided herein are compositions comprising exosomes comprising an immunomodulatory molecule, e.g., ICOSL or OX40L, on their surface. Further provided are methods of using such exosomes for the treatment of diseases requiring immunomodulation, such as cancer, autoimmune disease, or infectious disease.

Abstract: The present disclosure is directed to novel therapeutic approaches for the prevention, treatment and/or delaying progression of chronic injury, progressive loss of functional parenchymal cells, or fibrosis of an organ. Specifically disclosed are agents for use in increasing homodimer-formation of ARNT in an organ in the prevention, treatment and/or delaying progression of chronic injury, progressive loss of functional parenchymal cells, or fibrosis of said organ, as further defined in the claims. In embodiments, said agent may be (i) an inhibitor of protein phosphatase 2A (PP2A) activity, (ii) an inhibitor of the transcriptional repressor complex FKBP12/YY1, or (iii) an expression construct, which is capable of over-expressing ARNT in said organ, as well as combinations of (i), (ii), and/or (iii).

Abstract: Provided herein are compositions comprising exosomes comprising CD47 on their surface, and further comprising a CRISPR system. Further provided are methods of using the exosomes for gene editing and the treatment of cancer by gene editing.

Abstract: Methods for diagnosis and treatment of cancers by use of exosomes comprising miRNAs and precursors thereof. For example, in some aspects, a cancer may be diagnosed or evaluated by determining the miRNA content of exosomes in a sample from a subject or by detecting miRNA processing in exosomes.

Abstract: The present invention provides that exosomes from human body fluid samples contain double stranded genomic DNA that spans all chromosomes and may be used to determine the mutation status of genes of interest in diseases, such as cancer. Furthermore, the present invention provides the use of exosomes to produce therapeutic proteins and for their use in therapy as well as the detection of cancer cell-derived exosomes to diagnose cancer and monitor therapeutic response.

Abstract: The present invention provides that exosomes from human body fluid samples contain double stranded genomic DNA that spans all chromosomes and may be used to determine the mutation status of genes of interest in diseases, such as cancer. Furthermore, the present invention provides the use of exosomes to produce therapeutic proteins and for their use in therapy as well as the detection of cancer cell-derived exosomes to diagnose cancer and monitor therapeutic response.

Abstract: The present invention provides lipid-based nanoparticles (e.g., liposomes or exosomes) having CD47 on their surface and comprising a therapeutic agent (e.g., a therapeutic protein, an antibody, an inhibitory RNA, and/or a small molecule drug). Furthermore, the present invention provides for use of such lipid-based nanoparticles in therapy.

Abstract: The present invention provides lipid-based nanoparticles (e.g., liposomes or exosomes) having CD47 on their surface and comprising a therapeutic agent (e.g., a therapeutic protein, an antibody, an inhibitory RNA, and/or a small molecule drug). Furthermore, the present invention provides for use of such lipid-based nanoparticles in therapy.

Abstract: The present invention provides that exosomes from human body fluid samples contain double stranded genomic DNA that spans all chromosomes and may be used to determine the mutation status of genes of interest in diseases, such as cancer. Furthermore, the present invention provides the use of exosomes to produce therapeutic proteins and for their use in therapy as well as the detection of cancer cell-derived exosomes to diagnose cancer and monitor therapeutic response.

Abstract: The present invention provides that exosomes from human body fluid samples contain double stranded genomic DNA that spans all chromosomes and may be used to determine the mutation status of genes of interest in diseases, such as cancer. Furthermore, the present invention provides the use of exosomes to produce therapeutic proteins and for their use in therapy as well as the detection of cancer cell-derived exosomes to diagnose cancer and monitor therapeutic response.

Abstract: The present invention provides that exosomes from human body fluid samples contain double stranded genomic DNA that spans all chromosomes and may be used to determine the mutation status of genes of interest in diseases, such as cancer. Furthermore, the present invention provides the use of exosomes to produce therapeutic proteins and for their use in therapy as well as the detection of cancer cell-derived exosomes to diagnose cancer and monitor therapeutic response.

Abstract: Methods for diagnosis and treatment of cancers by use of exosomes comprising miRNAs and precursors thereof. For example, in some aspects, a cancer may be diagnosed or evaluated by determining the miRNA content of exosomes in a sample from a subject or by detecting miRNA processing in exosomes.

Abstract: The present invention relates to methods, compositions, and diagnostic tests for treating and diagnosing a subject with organ fibrosis or a risk of developing organ fibrosis. The present invention also relates to methods and compositions for treating a subject with a proliferative disease. In particular, the methods and compositions include treatment of organ fibrosis or a proliferative disease using an inhibitor of human epididymis protein-4 (HE4).

Abstract: The present invention relates to methods, compositions, and diagnostic tests for treating and diagnosing a metastatic as disease that results in increased mitochondrial respiration and/or biogenesis. In particular, the methods and compositions include treatment of metastatic diseases such as breast cancer using an antagonist of mitochondrial respiration such as a PGC1? antagonist.

Abstract: The invention features methods for diagnosing and treating pregnancy related complications. The invention also features methods for identifying compounds useful for treating pregnancy related complications.

Abstract: Methods and compositions for treating and/or preventing a pregnancy related disease or disorder are provided. The methods involve administration of 2-methoxyestradiol, or an analog thereof, to a subject. Also provided are methods for diagnosing or predicting a pregnancy related disease or disorder. The methods involve detection of 2-methoxyestradiol, or a precursor or metabolite thereof.

Abstract: The invention features methods for diagnosing and treating pregnancy related complications. The invention also features methods for identifying compounds useful for treating pregnancy related complications.